

**IN THE CLAIMS:**

Claim 9 was previously canceled. Claim 1 has been amended. New claims 10 and 11 have been added. All of the pending claims are presented below. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

**Listing of the Claims**

1. (Currently amended) A pharmaceutical composition for intramammary administration to a non-human mammal, said pharmaceutical composition providing increased anti-inflammatory efficacy while not increasing immunosuppressive side effects in the non-human mammal to which it has been administered, wherein:

the pharmaceutical composition comprises:

an antibacterial agent,

prednisolone, and

a pharmaceutically acceptable carrier; and

wherein the pharmaceutical composition comprises at least 20 mg of prednisolone per unit dose; and

further wherein the increased anti-inflammatory efficacy while not increasing immunosuppressive side effects may be determined by displaying a similar leukocyte count upon administration to the non-human mammal when administered intramammarily, as compared to the non-human mammal to whom the pharmaceutical composition has not been thus administered.

2. (Previously presented) The composition according to claim 1, wherein the composition comprises prednisolone in an amount of 20 to 40 mg per unit dose.

3. (Previously presented) The composition according to claim 2, wherein the composition comprises prednisolone in an amount of 20 to 30 mg per unit dose.

4. (Previously presented) The composition according to claim 1, wherein the antibacterial agent is a cephalosporin.

5. (Previously presented) The composition according to claim 4, wherein the cephalosporin is cephapirin.

6. (Previously presented) The composition according to claim 4, wherein the cephalosporin is cefquinome.

7. (Previously presented) The composition according to claim 1, wherein the composition comprises the antibacterial agent in an amount of 10 to 500 mg per unit dose.

8. (withdrawn) A process for preparing a pharmaceutical composition according to claim 1, comprising the steps of -mixing an oil and one or more pharmaceutically acceptable additives to form a carrier, and suspending the antibacterial agent and the prednisolone in the carrier.

9. (Canceled).

10. (New) A pharmaceutical composition for intramammary administration to a non-human mammal, the pharmaceutical composition providing increased anti-inflammatory efficacy while not increasing immunosuppressive side effects in the non-human mammal, wherein:

the pharmaceutical composition comprises:

an antibacterial agent;

at least 20 mg prednisolone per unit dose; and

a pharmaceutically acceptable carrier;

wherein the increased anti-inflammatory efficacy while not increasing immunosuppressive side effects may be determined by an increased chemotaxis of blood leukocytes upon administration to the non-human mammal when administered intramammarily, as compared to the non-human mammal to whom the pharmaceutical composition has not been thus administered.

11. (New) A pharmaceutical composition for intramammary administration to a non-human mammal, the pharmaceutical composition providing increased anti-inflammatory efficacy while not increasing immunosuppressive side effects in the non-human mammal, wherein:

the pharmaceutical composition comprises active agents and inactive agent, wherein the active agent consists of cephapirin and 20 mg prednisolone; and the inactive agent comprises a pharmaceutically acceptable carrier;

wherein the increased anti-inflammatory efficacy while not increasing immunosuppressive side effects may be determined by the non-human animal displaying a similar leukocyte count upon administration intramammarily thereto in comparison to the non-human mammal to which the pharmaceutical composition has not been thus administered.